Top Markets
#1 Cortex Cortex +173.67%
#2 GEKKO GEKKO +53.94%
#3 Helium Helium +32.96%
#4 Audiera Audiera +20.48%
#5 ADO Protocol ADO Protocol +17.96%
#6 Ontology Gas Ontology Gas +15.92%
#7 Pons Pons +15.26%
#8 COTI COTI +14.32%
#9 o1.exchange o1.exchange +13.62%
#10 TENDIES TENDIES +9.27%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

LBPH
Rank in Stocks #8563
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Share Price
$59.98
Last synced: 2024-12-13
Market Cap
$1.22B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Longboard Pharmaceuticals, Inc. (LBPH)

Category

Healthcare
P/E ratio for Longboard Pharmaceuticals, Inc. (LBPH)
P/E ratio as of August 2026 TTM: -25.10
According to Longboard Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -25.10. At the end of 2022 the company had a P/E ratio of -1.30.
P/E ratio history for Longboard Pharmaceuticals, Inc. from 2020 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -25.10 895.88%
2023 -2.52 94.07%
2022 -1.30 -56.80%
2021 -3.00 -85.30%
2020 -20.43 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -216.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -222.01%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -229.35%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -68.38%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.